Sodium-glucose cotransporter 2-inhibitors (SGLT2i) are increasingly prescribed for patients with type 2 diabetes (T2DM) and heart failure (HF) across the spectrum of ejection fraction, due to their cardiorenal and metabolic benefits (1). Amidst the considerable pill burden in this patient ...
In Europe, canagliflozin is labelled with an inverted black triangle in the package leaflet and the summary of product characteristics (SmPC),22 indicating that the drug is under © 2014 Macmillan Publishers Limited Nutrition & Diabetes (2014) 1 – 8 SGLT2 inhibitors: focus on canagliflozin B ...